April 12, 2021

COVID-19: Transparency mechanism in the export of COVID-19 vaccines outside EU

On March 11, 2021, following persistent delays in some deliveries of vaccine to the EU, the European Commission adopted the new Implementing Regulation (EU) 2021/442 (“New Implementing Regulation”), renewing, with amendments, through the end of June, the transparency and authorization mechanism for COVID-19 vaccine exports currently falling under CN code 3002 20 10, irrespective of their packaging and active substances, including master and working cell banks used for the manufacture of such vaccines, currently falling under CN codes ex 2933 99 80, ex 2934 99 90, ex 3002 90 90, and ex 3504 00 90.

This export authorization mechanism applies only to exports from companies with which the EU has concluded Advance Purchase Agreements (“APAs”). These APAs commit the vaccine producers to deliver to EU member states a pre-agreed number of vaccines.

This mechanism was initially put in place on January 30, 2021, with the adoption of Regulation (EU) 2021/111 of January 29, 2021 (“First Implementing Regulation”), and with a timeframe lasting until March 12, 2021 which was supposed to represent a sufficient term to allow the full production capacity for COVID-19 vaccines in the European Union to be reached, thus avoiding the risk of shortages and diversion of supplies.

Based on the First Implementing Regulation, on February 26, 2021, the Italian government sent to the European Commission its proposal for denying authorization to export 250,000 units of COVID-19 vaccines manufactured by AstraZeneca heading from Italy to Australia, thus applying for the first time said regulation. On March 2, 2021, that proposal was approved by the European Commission and, as a result, the Italian Ministry of Foreign Affairs formally issued the first export-denial order.

According to the New Implementing Regulation, requests for export authorization shall be processed within two working days. The draft decision of the member state authority is forwarded to the European Commission and reviewed by the same and then published. When a company that manufactures COVID-19 vaccines in an EU country applies for export authorization, the member state’s authorities must consider whether the export poses a threat to the execution of EU APAs with vaccines manufacturers. In addition, under the amended rules, member state authorities must consider whether the export would pose a threat to the supply of COVID-19 vaccines within the EU, meaning it must consider reciprocity and proportionality. Reciprocity means that the competent authority must assess whether the country of destination restricts its own exports to the EU of COVID-19 vaccines or of the raw materials from which they are made. Proportionality includes a review of the current COVID-19 situation in the export country in comparison to the EU, in particular a review of the epidemiological situation, vaccination rate, and vaccine supply.

Exports to certain low- and middle-income countries on the COVAX AMC list and for humanitarian purposes, among others, are not subject to the export authorization mechanism.

The context for this is that the European Union has supported the rapid development and production of several vaccines against COVID-19 with a total of EUR2.7 billion and finds it important to protect the integrity of this substantial investment from the EU budget. Thus, the European Commission is concerned by the lack of transparency around the ways some companies are operating and wants to have complete information in order to ensure they fulfill their contractual commitments.

To address this very serious and immediate public health issue, the commission has adopted a temporary export transparency and export authorization mechanism on the basis of Regulation (EU) 2015/479 on common rules for exports (full text accessible here). Thus, taking into account the persistent delays and failures on the part of several companies in honoring their agreements with the EU despite having received a down payment to enable sufficient production, the commission introduced the above measures to remedy this critical situation.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Follow us on
Follow us on